{"id":"placebo-of-afatinib","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T12:34:26.006525","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo formulations are inert substances used as control comparators in clinical trials to establish the efficacy of the active drug through blinded comparison. In this Phase 3 trial, the placebo arm allows researchers to distinguish genuine therapeutic effects of afatinib from natural disease progression or patient expectation effects.","oneSentence":"This is a placebo control arm and contains no active pharmaceutical ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:10.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT01824823","phase":"PHASE2","title":"Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2014-06-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":3},{"nctId":"NCT05445791","phase":"PHASE3","title":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2021-07-15","conditions":"Non Small Cell Lung Cancer","enrollment":312},{"nctId":"NCT05204758","phase":"PHASE3","title":"Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2016-05-12","conditions":"Advanced Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT01427478","phase":"PHASE3","title":"Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2011-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":134},{"nctId":"NCT02131155","phase":"PHASE3","title":"LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2014-07-17","conditions":"Head and Neck Neoplasms","enrollment":36},{"nctId":"NCT01345669","phase":"PHASE3","title":"LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-10-17","conditions":"Head and Neck Neoplasms","enrollment":617},{"nctId":"NCT00656136","phase":"PHASE3","title":"BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":585}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo of BIBW 2992"],"phase":"phase_3","status":"active","brandName":"Placebo of AFATINIB","genericName":"Placebo of AFATINIB","companyName":"Centre Leon Berard","companyId":"centre-leon-berard","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}